Gridsum to Announce Third Quarter 2016 Financial Results on November 21, 2016
Nov 02, 2016 12:01 pm UTC| Business
BEIJING, Nov. 02, 2016 -- Gridsum Holding Inc. (“Gridsum” or the “Company”) (NASDAQ:GSUM), a leading provider of sophisticated data analysis software in China, today announced that it plans to release its unaudited...
Momenta Pharmaceuticals Reports Third Quarter 2016 Financial Results
Nov 02, 2016 12:01 pm UTC| Business
--Company appoints Scott M. Storer as SVP and CFO-- --Initiates Phase 1 trial for M834, biosimilar ORENCIA® (abatacept) candidate-- CAMBRIDGE, Mass., Nov. 02, 2016 -- Momenta Pharmaceuticals,Inc. (Nasdaq:MNTA) today...
Momenta Pharmaceuticals Reports Third Quarter 2016 Financial Results
Nov 02, 2016 12:01 pm UTC| Business
--Company appoints Scott M. Storer as SVP and CFO-- --Initiates Phase 1 trial for M834, biosimilar ORENCIA® (abatacept) candidate-- CAMBRIDGE, Mass., Nov. 02, 2016 -- Momenta Pharmaceuticals,Inc. (Nasdaq:MNTA) today...
Argos Therapeutics Participating in 4th International mRNA Health Conference
Nov 02, 2016 12:01 pm UTC| Business
DURHAM, N.C., Nov. 02, 2016 -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis®...
Argos Therapeutics Participating in 4th International mRNA Health Conference
Nov 02, 2016 12:01 pm UTC| Business
DURHAM, N.C., Nov. 02, 2016 -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis®...
Nov 02, 2016 12:01 pm UTC| Business
CAMBRIDGE, Mass., HERTFORDSHIRE, England and PITTSBURGH, Nov. 02, 2016 -- Momenta Pharmaceuticals,Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today announced that dosing has begun in a Phase 1 study to...
Nov 02, 2016 12:01 pm UTC| Business
CAMBRIDGE, Mass., HERTFORDSHIRE, England and PITTSBURGH, Nov. 02, 2016 -- Momenta Pharmaceuticals,Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today announced that dosing has begun in a Phase 1 study to...